Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Borderline Resectable Pancreatic Ductal Adenocarcinoma: early-phase trial registry
4 of 4 indexed Borderline Resectable Pancreatic Ductal Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 4 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Borderline Resectable Pancreatic Ductal Adenocarcinoma: 4 US clinical trials tracked, 4 recruiting.
Borderline Resectable Pancreatic Ductal Adenocarcinoma is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Emory University, running 2 of these trials.
Enrollment posture brief
Registry condition borderline-resectable-pancreatic-ductal-adenocarcinoma
OPEN 4 | RECR 100% | LATE 0 | EARLY 3 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Borderline Resectable Pancreatic Ductal Adenocarcinoma lists 4 open slots (100% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Borderline Resectable Pancreatic Ductal Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Borderline Resectable Pancreatic Ductal Adenocarcinoma is recruiting above its size-band peers.
4 of 4 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
OHSU Knight Cancer Institute
NCT04005690
Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy
Emory University
NCT06595160
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
Emory University
NCT06423326
NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial
Roswell Park Cancer Institute
NCT06821997
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Borderline Resectable Pancreatic Ductal Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Borderline Resectable Pancreatic Ductal Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Borderline Resectable Pancreatic Ductal Adenocarcinoma page
4 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Borderline Resectable Pancreatic Ductal Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Emory University sponsors the most Borderline Resectable Pancreatic Ductal Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See Emory University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Borderline Resectable Pancreatic Ductal Adenocarcinoma condition card totals 4 registered trials; most-linked intervention Computed Tomography; top US site state Georgia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.